During the last session, Nektar Therapeutics (NASDAQ:NKTR)’s traded shares were 1.44 million, with the beta value of the company hitting 0.62. The 52-week high for the NKTR share is $1.93, that puts it down -124.42 from that peak though still a striking 24.42% gain since the share price plummeted to a 52-week low of $0.65. The company’s market capitalization is $158.86M, and the average trade volume was 2.05 million shares over the past three months.
Nektar Therapeutics (NKTR) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. NKTR has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.19.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Nektar Therapeutics (NKTR) registered a 0.38% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.38% in intraday trading to $0.86, hitting a weekly high. The stock’s 5-day price performance is 8.16%, and it has moved by 10.58% in 30 days. Based on these gigs, the overall price performance for the year is -4.31%.
The consensus price target of analysts on Wall Street is $18.5, which implies an increase of 95.35% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $24 respectively. As a result, NKTR is trading at a discount of -2690.7% off the target high and -597.67% off the low.
Nektar Therapeutics (NKTR) estimates and forecasts
In the rating firms’ projections, revenue will increase 17.53% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 36.66M as predicted by 9 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 22.39M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 23.89M and 21.64M respectively. In this case, analysts expect current quarter sales to grow by 53.48% and then jump by 3.47% in the coming quarter.
While earnings are projected to return 51.06% in 2025, the next five years will return 20.18% per annum.
NKTR Dividends
Nektar Therapeutics is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 15.16 million shares, is of BLACKROCK INC.’s that is approximately 7.7823% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $18.79 million.
